Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

William G. Ondo; Christine Hunter

doi:10.1002/mds.10426

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

William G. Ondo, Christine Hunter

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Manipulation of γ-aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1-minute hand-tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed.

Original language	English (US)
Pages (from-to)	683-685
Number of pages	3
Journal	Movement Disorders
Volume	18
Issue number	6
DOIs	https://doi.org/10.1002/mds.10426
State	Published - Jun 1 2003

Keywords

Basal ganglia
Flumazenil
Parkinson's disease
Therapeutic trial

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.10426

Fingerprint Dive into the research topics of 'Flumazenil, a GABA antagonist, may improve features of Parkinson's disease'. Together they form a unique fingerprint.

Cite this

@article{064392bf721c4dab8b42f82ff73ccb8c,

title = "Flumazenil, a GABA antagonist, may improve features of Parkinson's disease",

abstract = "Manipulation of γ-aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1-minute hand-tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed.",

keywords = "Basal ganglia, Flumazenil, Parkinson's disease, Therapeutic trial",

author = "Ondo, {William G.} and Christine Hunter",

year = "2003",

month = jun,

day = "1",

doi = "10.1002/mds.10426",

language = "English (US)",

volume = "18",

pages = "683--685",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

AU - Ondo, William G.

AU - Hunter, Christine

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Manipulation of γ-aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1-minute hand-tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed.

AB - Manipulation of γ-aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1-minute hand-tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed.

KW - Basal ganglia

KW - Flumazenil

KW - Parkinson's disease

KW - Therapeutic trial

UR - http://www.scopus.com/inward/record.url?scp=0038084254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038084254&partnerID=8YFLogxK

U2 - 10.1002/mds.10426

DO - 10.1002/mds.10426

M3 - Article

C2 - 12784272

AN - SCOPUS:0038084254

VL - 18

SP - 683

EP - 685

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this